The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 23, 2021

Filed:

Apr. 16, 2018
Applicant:

Arrowhead Pharmaceuticals, Inc., Pasadena, CA (US);

Inventors:

So Wong, Oregon, WI (US);

David L. Lewis, Madison, WI (US);

David B. Rozema, Cross Plains, WI (US);

Darren H. Wakefield, Fitchburg, WI (US);

Steven B. Kanner, Berkeley, CA (US);

Weijun Cheng, Middleton, WI (US);

Lauren J. Almeida, Madison, WI (US);

Andrei V. Blokhin, Fitchburg, WI (US);

Jeffrey C. Carlson, Madison, WI (US);

Anthony L. Nicholas, Oregon, WI (US);

Aaron Almeida, Madison, WI (US);

Jonathan D. Benson, Stoughton, WI (US);

Justin Woods, Fitchburg, WI (US);

Assignee:

Arrowhead Pharmaceuticals, Inc., Pasadena, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 31/713 (2006.01); A61K 45/06 (2006.01); A61K 47/60 (2017.01); A61K 47/64 (2017.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/713 (2013.01); A61K 45/06 (2013.01); A61K 47/60 (2017.08); A61K 47/64 (2017.08); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/343 (2013.01); C12N 2310/346 (2013.01); C12N 2310/351 (2013.01); C12N 2320/31 (2013.01); C12N 2320/32 (2013.01);
Abstract

RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2α (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2α RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2α RNAi triggers to tumor cells in vivo provides for inhibition of Hif2α gene expression and treatment of cancer.


Find Patent Forward Citations

Loading…